Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients
Author:
Funder
Instituto de Salud Carlos III
Ministerio de Economía y Competitividad
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference35 articles.
1. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015
2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015
3. Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer;Gettinger;J Clin Oncol,2015
4. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label, phase 3 trial;Weber;Lancet Oncol,2015
5. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015
Cited by 182 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The efficacy of immune checkpoint inhibitors following discontinuation for long‐term response or toxicity in advanced or metastatic non‐small‐cell lung cancers: A retrospective study;Health Science Reports;2024-01
2. Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients;Frontiers in Oncology;2023-12-19
3. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review;Japanese Journal of Clinical Oncology;2023-12-18
4. Analysis of immune‐related adverse events in gastrointestinal malignancy patients treated with immune checkpoint inhibitors;International Journal of Cancer;2023-12-11
5. Immune checkpoint inhibitors in advanced cutaneous melanoma: a systematic review and meta-analysis of efficacy and review of characteristics;Expert Review of Anticancer Therapy;2023-11-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3